Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Docusol Paediatric 12.5 mg/5 ml Oral Solution

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Docusate sodium may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Docusate sodium

Equivalent medicines (same active substance, strength and form)

Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

FOR Docusol Paediatric Solution is one of a group of medicines called 'laxatives'. They are usually used to prevent and treat constipation. Docusol Paediatric Solution may also be used before a stomach X ray.

2. WHAT YOU NEED TO KNOW BEFORE THE PATIENT TAKES DOCUSOL PAEDIATRIC SOLUTION Do not give Docusol Paediatric Solution

  • if the patient is allergic to docusate sodium or any of the other ingredients of this medicine (listed in section 6).
  • if the patient is suffering from stomach pains or an obstruction in the gut.
  • if the patient is feeling sick or has been sick in the last 24 hours. Warnings and precautions Talk to the patient's doctor or pharmacist before the patient starts taking Docusol Paediatric Solution.
  • Docusol Paediatric Solution should not be given to infants under the age of 6 months.
  • Prolonged use can cause the gut to become lazy and not work properly. Other medicine and Docusol Paediatric Solution Tell the patient's doctor or pharmacist if the patient is taking, have recently taken or might take any other medicines. Docusol Paediatric Solution should not be taken if the patient is already taking mineral oil. Patients already taking other laxatives called anthraquinone laxatives such as senna, will need to take reduced doses as Docusol Paediatric Solution increases their effects. Taking Docusol Paediatric Solution with food and drink Docusol Paediatric Solution can be taken with food and drink.

Important information about some of the ingredients of Docusol Paediatric Solution Docusol Paediatric Solution contains methyl p-hydroxybenzoate and propyl p-hydroxybenzoate. This medicine contains 5 mg of methyl p-hydroxybenzoate and 2.5 mg of propyl p-hydroxybenzoate in each dose (5ml). May cause allergic reactions (possibly delayed).

Docusol Paediatric Solution contains sorbitol. This medicine contains 1290 mg of sorbitol in each dose (5 ml). Sorbitol is a source of fructose. If the patient's doctor has told you that the patient has an intolerance to some sugars or if the patient has been diagnosed with hereditary fructose intolerance (HFI), a rare genetic disorder in which a person cannot break down fructose, talk to a doctor before the patient takes this medicine. Sorbitol may cause gastrointestinal discomfort and mild laxative effect. Docusol Paediatric Solution contains aspartame. This medicine contains 15 mg of aspartame per dose (5 ml). Aspartame is a source of phenylalanine. It may be harmful if you have phenylketonuria (PKU), a rare genetic disorder in which phenylalanine builds up because the body cannot remove it properly. Docusol Paediatric Solution contains sodium This medicine contains less than 1 mmol sodium (23 mg) per 5 mL dose, that is to say essentially 'sodium-free'.

How to take it

DOCUSOL PAEDIATRIC SOLUTION Always take this medicine exactly as described in this leaflet or as the patient's doctor or pharmacist have told you. Check with the patient's doctor or pharmacist if you are not sure.

Constipation: The recommended dose for infants aged over 6 months is one 5ml spoonful three times a day. The recommended dose for children aged 2-12 years is one to two 5ml spoonfuls three times a day. Dilute the medicine in a glass of flavoured drink such as fruit juice or milk and give to the patient to drink within 30 minutes of preparation. This medicine should not be given to infants under the age of 6 months. Reduce the dose as the condition improves. Use before stomach X-ray: When taken before a stomach X-ray the dose is six 5ml spoonfuls, as a single dose. Docusate sodium may cause an unpleasant aftertaste or burning sensation. This may be minimised by drinking plenty after taking the solution. If the patient takes more Docusol Paediatric Solution than they should If the patient takes more Docusol Paediatric Solution than they should, the patient should drink lots of water. The nearest hospital casualty department should be contacted or the patient's doctor must be informed immediately. If the patient forgets to take Docusol Paediatric Solution Give the patient their usual dose and then continue the normal course of treatment. Do not give a double dose to make up for a forgotten dose. If you have any further questions on the use of this product, ask the doctor or pharmacist.

Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. If any of the following happen, stop taking Docusol Paediatric Solution and tell your doctor as soon as possible: Rare: may affect up to 1 in 1,000 people

  • Diarrhoea
  • Feel sick
  • Stomach cramps Not known: frequency cannot be estimated from the available data
  • Skin rash
  • Pruritus (itching) If the patient needs to take a laxative every day, or if the patient has a persistent stomach ache, they must see their doctor. Docusate sodium may cause an unpleasant aftertaste or burning sensation. This may be minimised by drinking plenty of water after taking the solution. If any of the side effects gets serious, or if the patient notices any side effects not listed in this leaflet, please tell the patient's doctor or pharmacist. Reporting of side effects If the patient gets any side effects, talk to the patient's doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

How to store it

DOCUSOL PAEDIATRIC SOLUTION This medicinal product does not require any special storage conditions. Keep this medicine out of the sight and reach of children. Do not use Docusol Paediatric Solution after the expiry date that is stated on the bottle label and carton after EXP. The expiry date refers to the last day of that month. Medicines should not be disposed of via wastewater or household waste. Do not throw away medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.

Contents of the pack and other information

What Docusol Paediatric Solution contains

  • The active substance is docusate sodium (12.5mg/5ml)
  • The other ingredients are sorbitol (E420), glycerol (E422), povidone, monosodium phosphate dihydrate, disodium phosphate dodecahydrate, methyl p-hydroxybenzoate (E218), propyl p-hydroxybenzoate (E216), strawberry flavour, aspartame (E951) and purified water. What Docusol Paediatric Solution looks like and contents of the pack Docusol Paediatric Solution is a clear liquid available in amber glass bottles of 125ml and 300ml with a plastic screw cap. Marketing Authorisation Holder and Manufacturer: Marketing Authorisation Holder: Typharm Ltd, Unit 1, 39 Mahoney Green, Rackheath, Norwich, NR13 6JY. Manufacturer Laboratórios Basi – Industria Farmacêutica, S.A., Parque Industrial Manuel Lourenco Ferreira, Lotes 8, 15 e 16 3450-232 Mortágua, Portugal This leaflet was last revised in October 2023

2/DP/05/2310/820.v4

Frequently asked questions about Docusol Paediatric 12.5 mg/5 ml Oral Solution

How do I take Docusol Paediatric 12.5 mg/5 ml Oral Solution?

Docusol Paediatric 12.5 mg/5 ml Oral Solution comes as oral solution containing 12.5mg / 5ml. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in Docusol Paediatric 12.5 mg/5 ml Oral Solution?

The active substance in Docusol Paediatric 12.5 mg/5 ml Oral Solution is docusate sodium.

Are there equivalent medicines to Docusol Paediatric 12.5 mg/5 ml Oral Solution?

Medicines with the same active substance, strength and form include: Docusate Sodium Paediatric 12.5mg/5ml Oral Solution. They are interchangeable only if your prescriber or pharmacist says so.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Docusol Paediatric 12.5 mg/5 ml Oral Solution, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Docusol Paediatric 12.5 mg/5 ml Oral Solution without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Docusate sodium (8 medicines)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

a) To prevent and treat chronic constipation

b) As an adjunct in abdominal radiological procedures

4.2. Posology and method of administration

Posology

Children: one to two 5ml spoonfuls three times daily. Dilute the medicine in a glass of flavoured drink e.g. fruit juice or milk. Drink the diluted medicine within 30 minutes of preparation.

Infants (Over six months): one 5ml spoonful three times daily. Dilute the medicine in a glass of flavoured drink e.g. fruit juice or milk. Drink the diluted medicine within 30 minutes of preparation.

Adults: not appropriate for adults or elderly. For administration to adults use

Docusol Adult Solution.

For barium meals: 30ml to be taken with meal.

Method of administration

Oral use.

4.3. Contraindications

Docusol solution should not be taken:

• by patients with a known hypersensitivity to docusate sodium or to any of the excipients listed in section 6.1.

• in the presence of abdominal pain, intestinal obstruction, nausea or if vomiting occurs.

4.4. Special warnings and precautions for use

Docusol Paediatric should not be given to infants under six months. Prolonged use can precipitate the onset of an atonic non-functioning colon and hypokalaemia.

Docusol Paediatric contains sorbitol.

This medicine contains 1290 mg sorbitol in each dose (5 mL). Sorbitol is a source of fructose. If the patient has an intolerance to some sugars or has herediatary fructose intolerance (HFI), a rare genetic disorder, the patient must not receive this medicine. Patients with HFI cannot break down fructose, which may cause serious side effects. Sorbitol may cause gastrointestinal discomfort and mild laxative effect.

Docusol Paediatric contains 5 mg methyl p-hydroxybenzoate and 2.5 mg propyl p-hydroxybenzoate in each 5 mL dose.

May cause allergic reactions (possibly delayed).

Docusol Paediatric contains aspartame.

This medicine contains 15 mg of aspartame per dose (5 mL). Aspartame is a source of phenylalanine. It may be harmful to patients with phenylketonuria (PKU), a rare genetic disorder in which phenylalanine builds up because the body cannot remove it properly.

Docusol Paediatric contains sodium.

This medicine contains less than 1 mmol sodium (23 mg) per 5 mL dose, that is to say essentially 'sodium-free'.

4.5. Interaction with other medicinal products and other forms of interaction

Docusol solution should not be taken concurrently with mineral oil. Anthraquinone derivatives should be taken in reduced doses, if administered with Docusol as their absorption is increased.

4.6. Fertility, pregnancy and lactation

Pregnancy

There is inadequate evidence of safety of the drug in human pregnancy, nor is there evidence from animal work that it is free from hazard, but it has been in wide use for many years without apparent ill consequence. Use in pregnancy only if the benefits outweigh the potential risks.

Breastfeeding

Docusate sodium is excreted in breast milk and should therefore be used with caution in lactating mothers.

4.7. Effects on ability to drive and use machines

None known.

4.8. Undesirable effects

Frequencies are defined as follows: Very common (≥ 1/10); common (≥ 1/100 to ≤ 1/10); uncommon (≥ 1/1,000 to ≤ 1/100); rare (≥ 1/10,000 to ≤ 1/1,00); very rare (≤ 1/10,000), not known (cannot be estimated from the available data).

Gastrointestinal disorders:

Rare: diarrhoea, nausea, abdominal cramps.

Skin and subcutaneous tissue disorders:

Not known: skin rash and pruritus.

There have been spontaneous reports of burning sensation in mouth and throat following the use of docusate sodium. Patients are advised to drink plenty of water or flavoured drink after taking the solution.

Reporting of suspected adverse reactions

Reporting suspected adverse reaction after authorisation of the medicinal product is important. It allows continued monitoring of the benefit / risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App store.

4.9. Overdose

In rare cases of overdose excessive loss of water and electrolytes should be treated by encouraging the patient to drink plenty of fluid.

💬 Ask about this leaflet

Ask anything about Docusol Paediatric 12.5 mg/5 ml Oral Solution. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →